Virpax Pharmaceuticals (NASDAQ:VRPX) & Iterum Therapeutics (NASDAQ:ITRM) Critical Contrast

Iterum Therapeutics (NASDAQ:ITRMGet Free Report) and Virpax Pharmaceuticals (NASDAQ:VRPXGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Earnings & Valuation

This table compares Iterum Therapeutics and Virpax Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Iterum Therapeutics N/A N/A -$38.37 million ($2.65) -0.43
Virpax Pharmaceuticals N/A N/A -$15.19 million N/A N/A

Insider & Institutional Ownership

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 5.6% of Iterum Therapeutics shares are owned by insiders. Comparatively, 4.2% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Iterum Therapeutics and Virpax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iterum Therapeutics N/A -664.00% -104.17%
Virpax Pharmaceuticals N/A -345.87% -161.82%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Iterum Therapeutics and Virpax Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iterum Therapeutics 0 0 1 0 3.00
Virpax Pharmaceuticals 0 1 0 0 2.00

Iterum Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 429.43%. Given Iterum Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Iterum Therapeutics is more favorable than Virpax Pharmaceuticals.

Risk & Volatility

Iterum Therapeutics has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Summary

Iterum Therapeutics beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Virpax Pharmaceuticals

(Get Free Report)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.